8-K: Interpace Biosciences Achieves Record Revenue and Profitability in Second Quarter 2024

Interpace Biosciences reported record revenue, test volume, and cash collections for Q2 2024, driven by increased adoption of its molecular diagnostic tests and improved operational efficiency.

Summary

• Interpace Biosciences announced its financial results for the second quarter ended June 30, 2024.
• The company reported net revenue of $12.0 million, a 9% increase from $11.0 million in the same quarter of the previous year.
• Test volume increased by 12% year-over-year, reaching record levels.
• Cash collections for the quarter were $11.0 million, up 7% from $10.2 million in the prior-year quarter.
• Operating expenses were reduced by approximately 14% compared to Q2 2023.
• Income from continuing operations was $2.1 million, an improvement from $0.4 million in the prior-year quarter.
• Adjusted EBITDA for Q2 2024 was $2.3 million, compared to $1.3 million in Q2 2023.
• The company's cash balance as of June 30, 2024, was $2.0 million, down from $5.1 million on June 30, 2023, due to a $4.6 million paydown of long-term debt.

Sentiment

Score: 8

Explanation: The document reflects a very positive sentiment due to strong financial performance, record results, and continued growth. However, the company's history of operating losses and potential challenges related to reimbursement and financing slightly temper the overall sentiment.

Positives

• The company achieved profitability and positive cash flow in Q2 2024.
• Continued adoption of the company's proprietary molecular diagnostics tests (ThyGeNEXT + ThyraMIRv2 and PancraGEN) by physicians and medical professionals.
• The company's testing platform for indeterminate thyroid nodules provides very high NPV and PPV results.
• Interpace's testing services for pancreatic cyst fluid offer convenience by allowing multiple tests to be run from a single specimen.
• The company made additional investments in its sales force.
• The company made additional principal payments on its long-term debt, improving its balance sheet.

Negatives

• The company's cash balance decreased from $5.1 million on June 30, 2023, to $2.0 million on June 30, 2024.
• The company has a history of operating losses.
• The company's common stock may be removed from trading on the OTCQX.

Risks

• Reimbursement of the company's tests is subject to review by CMS.
• The company's ability to continue to perform, bill, and receive reimbursement for its PancraGEN molecular test under the existing local coverage determination (LCD) is uncertain, as the LCD is currently under review.
• The company's estimates of future revenue, cash flows, and adjusted EBITDA may prove to be materially inaccurate.
• The company may need to seek alternative sources of financing.
• The company is dependent on sales and reimbursements from its clinical services.
• The company relies on third parties to process and transmit claims to payers, and any disruption in this process could adversely impact the company.
• The company's revenue recognition is based in part on estimates for future collections, which may prove to be incorrect.

Future Outlook

The document does not explicitly provide specific future financial guidance, but it suggests a positive outlook based on continued growth in test volume and adoption of the company's diagnostic tests.

Management Comments

• 'The cash position of the Company allowed for additional investments in our sales force, while simultaneously improving income from continuing operations. This also supported additional principal payments on our long-term debt, continuing to improve the Companys balance sheet.', said Chris McCarthy, Chief Financial Officer.
• 'Q2 2024 represented record testing volume for the Company, resulting in the achievement of continued profitability and positive cash flow.', stated Tom Burnell, President and CEO.
• 'Continued adoption of the Companys proprietary molecular diagnostics tests (ThyGeNEXT + ThyraMIRv2 and PancraGEN) by physicians and medical professionals has fueled the continued growth trajectory of the Company.', Burnell added.
• 'Q2 2024 marked the sixteenth consecutive quarter of year-over-year volume growth for the Company.', Burnell added.
• 'Interpace is uniquely positioned with our portfolio of testing services that offer physicians both confidence and convenience when determining patient management strategies of surgery or surveillance.', said Rob Renjilian, Senior Vice President of Marketing.
• 'Our testing platform for indeterminate thyroid nodules provides very high NPV and PPV results. This allows physicians the ability to both rule-in and rule-out thyroid cancer, while also offering the convenience of simple specimen handling because no vial refrigeration or ice for shipping are needed.', Mr. Renjilian added.
• 'Splitting and sending specimens to different labs is not needed when using Interpaces testing services for pancreatic cyst fluid. With one specimen, we can run first-line fluid chemistry tests, such as CEA and glucose, and also provide molecular testing when indicated. Our testing differentiates pancreatic cysts from high to low malignancy potential with reliable clinical outcomes proven by up to 8 years of follow-up.', Mr. Renjilian continued.

Industry Context

This announcement highlights the growing importance of molecular diagnostics in personalized medicine, particularly in the diagnosis and management of thyroid and pancreatic cancers. Interpace is positioning itself as a leader in this space by offering a comprehensive suite of tests that can help guide treatment decisions.

Comparison to Industry Standards

• Interpace's ThyGeNEXT and ThyraMIRv2 tests for thyroid cancer diagnosis compete with similar offerings from companies like Veracyte (Afirma) and CareDx (ThyraMIR).
• Interpace's PancraGEN test for pancreatic cancer diagnosis competes with tests from companies like Myriad Genetics (myRisk) and Natera (Signatera).
• Interpace's reported 62% gross profit margin is within the typical range for diagnostic companies, which generally have gross margins between 50% and 70%.
• Veracyte reported a gross margin of 68% in their most recent quarterly report, while CareDx reported a gross margin of 67%.
• Myriad Genetics reported a gross margin of 71% in their most recent quarterly report, while Natera reported a gross margin of 52.5%.

Stakeholder Impact

• Shareholders: Potential positive impact due to improved financial performance and growth prospects, but also risks associated with the company's history of losses and potential delisting from OTCQX.
• Employees: Positive impact due to the company's growth and investment in its sales force.
• Customers: Positive impact due to the availability of advanced diagnostic tests that can improve patient care.
• Suppliers: No significant impact mentioned in the document.
• Creditors: Positive impact due to the company's improved financial performance and debt reduction.

Next Steps

• Continue to drive adoption of the company's molecular diagnostic tests.
• Gather clinical evidence and data to support payer reimbursement for BarreGEN.
• Monitor the review of the LCD for PancraGEN by Novitas Solutions, Inc.

Key Dates

Keywords

Interpace Biosciences, molecular diagnostics, thyroid cancer, pancreatic cancer, personalized medicine, ThyGeNEXT, ThyraMIRv2, PancraGEN, PanDNA, RespriDX, BarreGEN, financial results, Q2 2024, biotechnology